Tango Therapeutics (TNGX) Revenue & Revenue Breakdown
Tango Therapeutics Revenue Highlights
Latest Revenue (Y)
$42.07M
Latest Revenue (Q)
$11.61M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
Collaboration Revenue
Tango Therapeutics Revenue by Period
Tango Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $42.07M | 15.17% |
| 2023-12-31 | $36.53M | 46.93% |
| 2022-12-31 | $24.86M | -32.89% |
| 2021-12-31 | $37.04M | 383.83% |
| 2020-12-31 | $7.66M | -68.94% |
| 2019-12-31 | $24.65M | - |
Tango Therapeutics generated $42.07M in revenue during NA 2024, up 15.17% compared to the previous quarter, and up 170.67% compared to the same period a year ago.
Tango Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $11.61M | -41.60% |
| 2024-06-30 | $19.88M | 207.14% |
| 2024-03-31 | $6.47M | 19.15% |
| 2023-12-31 | $5.43M | -49.39% |
| 2023-09-30 | $10.73M | -26.48% |
| 2023-06-30 | $14.60M | 153.17% |
| 2023-03-31 | $5.77M | -10.06% |
| 2022-12-31 | $6.41M | -7.36% |
| 2022-09-30 | $6.92M | 19.91% |
| 2022-06-30 | $5.77M | 0.23% |
| 2022-03-31 | $5.76M | 0.73% |
| 2021-12-31 | $5.72M | -15.78% |
| 2021-09-30 | $6.79M | -62.61% |
| 2021-06-30 | $18.15M | 184.26% |
| 2021-03-31 | $6.39M | -30.15% |
| 2020-12-31 | $9.14M | -181.18% |
| 2020-09-30 | $-11.26M | -322.37% |
| 2020-06-30 | $5.06M | 7.49% |
| 2020-03-31 | $4.71M | - |
Tango Therapeutics generated $11.61M in revenue during Q3 2024, up -41.60% compared to the previous quarter, and up 79.51% compared to the same period a year ago.
Tango Therapeutics Revenue Breakdown
Tango Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Collaboration Revenue | $29.97M | $31.53M | $24.86M | $26.04M |
| License Revenue | $12.10M | $5.00M | $11.00M | - |
Tango Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (71.24%), and License Revenue (28.76%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $18.36M | $11.61M | $11.20M | $10.73M | $9.60M | $6.41M | $6.92M | $5.77M | $5.72M | $6.79M |
| License Revenue | - | $12.10M | - | $5.00M | $5.00M | - | $11.00M | - | - | - |
Tango Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (100.00%).
Tango Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 |
|---|---|---|
| Collaboration Revenue | $24.86M | $26.04M |
| License Revenue | - | $11.00M |
Tango Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Collaboration Revenue (100.00%).
Tango Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $263.40M | $102.40M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
| NRIX | Nurix Therapeutics | $54.55M | $18.45M |
| KYMR | Kymera Therapeutics | $47.07M | $3.74M |
| TNGX | Tango Therapeutics | $42.07M | $11.61M |
| STOK | Stoke Therapeutics | $36.55M | $4.89M |
| CNTB | Connect Biopharma | $26.03M | - |
| FHTX | Foghorn Therapeutics | $22.60M | $7.81M |
| RLAY | Relay Therapeutics | $10.01M | - |
| XLO | Xilio Therapeutics | $6.34M | $2.36M |
| STTK | Shattuck Labs | $5.72M | $1.61M |
| RLYB | Rallybio | $636.00K | $299.00K |
| CGEM | Cullinan Oncology | - | - |
| RAPT | RAPT Therapeutics | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| RVMD | Revolution Medicines | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| THRD | Third Harmonic Bio | - | - |
| PLRX | Pliant Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| TYRA | Tyra Biosciences | - | - |